MDWD Key Statistics, Chart & Performance
The current stock price of MDWD is 17.22 USD. In the past month the price decreased by -11.1%. In the past year, price decreased by -5.02%.
MDWD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD is a bad performer in the overall market: 69.97% of all stocks are doing better.
MDWD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. Both the profitability and financial health of MDWD have multiple concerns.
MDWD Financial Highlights
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 34.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.82% | ||
| ROE | -41.08% | ||
| Debt/Equity | 0.16 |
MDWD Forecast & Estimates
12 analysts have analysed MDWD and the average price target is 32.13 USD. This implies a price increase of 86.59% is expected in the next year compared to the current price of 17.22.
For the next year, analysts expect an EPS growth of 29.9% and a revenue growth 11% for MDWD
MDWD Ownership
MDWD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.13 | 293.697B | ||
| PFE | PFIZER INC | 8.82 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.8 | 117.3B | ||
| ZTS | ZOETIS INC | 18.5 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.5 | 25.214B | ||
| VTRS | VIATRIS INC | 5.68 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.06 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.39 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDWD
Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 111
Phone: 972779714100
MEDIWOUND LTD / MDWD FAQ
What does MDWD do?
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
What is the current price of MDWD stock?
The current stock price of MDWD is 17.22 USD. The price decreased by -2.27% in the last trading session.
Does MDWD stock pay dividends?
MDWD does not pay a dividend.
What is the ChartMill rating of MEDIWOUND LTD stock?
MDWD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting MDWD stock to perform?
12 analysts have analysed MDWD and the average price target is 32.13 USD. This implies a price increase of 86.59% is expected in the next year compared to the current price of 17.22.
How is the valuation of MEDIWOUND LTD (MDWD) based on its PE ratio?
MEDIWOUND LTD (MDWD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
Who owns MEDIWOUND LTD?
You can find the ownership structure of MEDIWOUND LTD (MDWD) on the Ownership tab.